Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. März 2023 09:05 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
16. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
08. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
06. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Issues Letter to Stockholders

Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
28. Februar 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
17. Februar 2023 08:55 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
17. Januar 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
17. Januar 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、アストラゼネカ (AstraZeneca) およびエラスムスメディカルセンター (Erasmus Medical Center) と、膵臓がんに関する臨床研究契約を締結

フロリダ州オカラ発, Jan. 17, 2023 (GLOBE NEWSWIRE) -- 複数のタイプのがんや免疫障害、ウイルス性疾患 (SARS-CoV-2ウイルスが原因で発症する新型コロナウイルス感染症を含む) の治療法の研究開発に注力する免疫製薬会社であるAIMイムノテック (AIM ImmunoTech Inc: AIM)...
17. Januar 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech与AstraZeneca和伊拉斯谟医疗中心签订胰腺癌临床研究协议

佛罗里达州奥卡拉, Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所代码：AIM）（以下简称“AIM...
09. Januar 2023 08:05 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...

Vorherige Seite

Nächste Seite